Trial Profile
A Retrospective Cohort Study of Self-reported Adherence to Regorafenib in Patients with Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2017
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 17 Mar 2017 New trial record
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium